Is enclomiphene just purified Clomid?
Clomiphene citrate contains two geometric isomers: trans-clomiphene, called enclomiphene, and cis-clomiphene, called zuclomiphene. Reviews often describe the mixture as roughly 60:40, while current US product labeling permits 30% to 50% of the cis isomer.19 Enclomiphene products contain the trans isomer alone. That is a real composition difference, but it does not by itself prove a difference in symptoms or long-term outcomes.
Both are intended to increase endogenous LH and FSH through estrogen-receptor modulation. Response generally requires a functioning hypothalamic-pituitary-gonadal axis and testes capable of answering the signal. Elevated LH and FSH suggesting primary testicular failure predict a poor response, so diagnosis matters before either drug is considered.
“The formulation difference is proven. A clinical advantage still has to be measured.”
What does the zuclomiphene in Clomid actually do?
The clearest human evidence concerns exposure, not clinical effect. In single-dose pharmacokinetic work, zuclomiphene was eliminated far more slowly than enclomiphene and was still detectable in blood up to a month after one 50 mg dose, a finding worth its caveat: that study was conducted in women.2
On daily dosing the slower-clearing isomer accumulates. In a prospective series of 15 men taking clomiphene 25 mg every day for at least six weeks, median serum zuclomiphene sat at 44.0 ng/mL against 2.2 ng/mL of enclomiphene.3 Those concentrations demonstrate different exposure. They do not establish which isomer contributes more to efficacy or adverse effects. FDA reviewers likewise concluded that proposed undesirable effects of zuclomiphene remain incompletely understood.10
What does the isomer evidence actually establish?
Separating measured findings from inference keeps the chemistry from doing more work than the clinical data.
| Evidence level | What is established | What is not established |
|---|---|---|
| Chemistry and exposure | Clomiphene contains geometric cis and trans isomers; the cis isomer persisted at a higher serum concentration in 15 treated men.39 | Serum concentration does not identify the isomer responsible for benefit or harm. |
| Comparative clinical signal | One sequential 66-man chart review favored enclomiphene for recorded adverse effects and estradiol.4 | The design cannot establish causation, and a larger 2026 abstract found no testosterone or estradiol treatment difference over time.11 |
| Patient outcomes | A small retrospective infertility study reported semen-parameter changes, but neither drug has a randomized head-to-head trial showing superiority.8 | No evidence proves that removing zuclomiphene improves symptoms, pregnancy, live birth or long-term safety. |
Does one raise testosterone more?
Available data do not establish that either drug raises testosterone more. The main direct comparison was a sequential chart review of 66 men treated first with clomiphene and later with enclomiphene, with no washout and different median exposure durations. Testosterone rose by a median 166 ng/dL on enclomiphene and 98 ng/dL on clomiphene, but the difference was not statistically significant (P=.20).4
A 2023 meta-analysis in obese men with androgen deficiency found clomiphene's pooled testosterone rise numerically larger, 11.56 nmol/L against 7.50 nmol/L for enclomiphene, with the caveat that those figures come from different studies pooled together, not from men randomized between the two drugs.5 They cannot be used as a head-to-head ranking. The randomized trials behind a 2025 meta-analysis compared these drugs against placebo, testosterone gel or hCG, never against each other.6 No head-to-head randomized trial has settled the comparison. If the real question is whether either beats replacing testosterone outright, that fork is covered in enclomiphene vs TRT.
What comparative side-effect signals exist?
In the same sequential 66-man chart review, adverse effects were recorded less often during enclomiphene treatment: decreased libido, reduced energy and mood changes were each reported significantly more often on clomiphene, and the overall odds of an adverse effect on enclomiphene were roughly a fifth of those on clomiphene (odds ratio 0.18, 95% confidence interval 0.07 to 0.44).4 Different treatment durations and chart-based symptom capture mean the study cannot establish that enclomiphene caused the difference.
Estradiol moved in opposite directions in that series: a median rise of 17.50 pg/mL on clomiphene against a median fall of 5.92 pg/mL on enclomiphene.4 A significant estradiol rise on clomiphene also appears in the largest long-term series.7 But a larger 2026 retrospective conference abstract, including 72 enclomiphene and 861 clomiphene patients, found no treatment difference over time in testosterone or estradiol.11 That abstract is not a full paper, but it argues against presenting the earlier pattern as a drug property.
Clomiphene labeling gives a specific safety instruction: new visual symptoms warrant stopping clomiphene and prompt complete ophthalmologic evaluation. Some disturbances have persisted after discontinuation.9 Enclomiphene is unapproved and has no equivalent approved label, so urgent prescriber guidance is more accurate than assuming its visual-risk magnitude is identical. The other treatment men weigh against enclomiphene on this same keep-your-own-production logic is hCG; that comparison is in enclomiphene vs hCG.
Why is Clomid easier to get?
Because clomiphene is an approved drug and enclomiphene is not. Clomiphene citrate is an FDA-approved generic, approved for female infertility and prescribed off-label in men for decades, and retail pharmacies can fill it. Enclomiphene has undergone substantial FDA and EMA review but has never been approved. Regulators concluded that testosterone and semen surrogates did not demonstrate meaningful clinical benefit. EMA also cited venous thromboembolism cases, including one fatal event, while causality and incidence remained uncertain.1012 FDA review is not FDA approval, and lack of approval is not lack of review.
FDA currently lists enclomiphene in Category 1 for patient-specific compounding under interim enforcement discretion.13 That is not an approval or a finding of safety and effectiveness. Cash costs vary by pharmacy, location, dose, coupon, insurance and whether clinical visits or labs are bundled. The full price picture is in our enclomiphene cost breakdown.
“One product is approved for another population. The other was reviewed but never approved.”
Is long-term use safe?
Nobody has run the study that would settle that word, and the longest record belongs to Clomid, not enclomiphene. In a two-centre review of 400 men on clomiphene for up to 7 years, the group had a mean follow-up of 25.5 months. Only 120 remained treated longer than 3 years, with a mean follow-up of 51.9 months. In that subgroup, 88% reached a normal testosterone level, 77% reported improved symptoms, 8% reported side effects, and no serious adverse event was recorded in the cohort.7 That dataset is retrospective and uncontrolled, so it can only report what someone wrote down; it is reassurance, not proof.
Enclomiphene has no equivalent. No multi-year dataset of comparable size has been published for the purified isomer, so long-term use extends the clomiphene record to enclomiphene on mechanistic reasoning rather than direct evidence. The practical consequence is unglamorous on either drug: periodic blood work and an ongoing prescriber relationship are part of the deal for as long as treatment continues.
Enclomiphene vs Clomid at a glance
The whole comparison in one table, with the evidence quality flagged where it is thin.
| Difference | Enclomiphene | Clomid |
|---|---|---|
| Composition | The trans geometric isomer of clomiphene, isolated1 | Two geometric isomers; current labeling permits 30% to 50% cis-clomiphene9 |
| FDA status | Not approved Reviewed by FDA and EMA; Category 1 interim compounding discretion1013 | Approved generic Approved for female infertility; prescribed off-label in men |
| Cash-cost comparison | Varies by dose, pharmacy, location, coupon, insurance and bundled clinical services; compare like with like on the same date. | |
| Testosterone effect | Median +166 ng/dL in one sequential chart review; the between-drug difference was not significant4 | Median +98 ng/dL in that review; no randomized head-to-head comparison exists4 |
| Estradiol behaviour | Median change of -5.92 pg/mL in one chart review; not reproduced as a treatment difference in a larger 2026 abstract411 | Median change of +17.50 pg/mL in that review; the 2026 abstract found no treatment difference over time411 |
| Side-effect signal | Fewer charted events in one sequential review, OR 0.18 (95% CI 0.07 to 0.44)4 | More charted libido, energy and mood complaints in that review; causation not established4 |
| Long-term data | No multi-year dataset published | 400-patient retrospective cohort; 120 treated beyond 3 years, with 8% reporting side effects in that subgroup7 |
| Availability | Patient-specific compounding under current interim FDA policy | Any ordinary pharmacy, with a prescription |
Common questions
Can you switch from Clomid to enclomiphene?
A clinician can switch a patient, but no randomized trial has established a washout period or dose conversion.
The main direct comparison was a sequential chart review with no washout and unequal treatment durations, so hormone levels and symptoms need reassessment rather than an assumed equivalent dose.
Why do many doctors prescribe Clomid off-label instead of enclomiphene?
Clomiphene is an FDA-approved generic for female infertility and can be prescribed off-label to men.
Enclomiphene was reviewed by FDA and EMA but never approved, and US access depends on patient-specific compounding under FDA interim enforcement discretion. That is a different regulatory and evidence position, not proof that either option is best for an individual.
Which is better for fertility?
Both are used when maintaining endogenous LH and FSH signalling is a goal, and small studies report maintained or improved semen measures.
No randomized enclomiphene-versus-clomiphene trial has shown superiority for pregnancy or live birth, so semen and hormone surrogates cannot establish a fertility winner.
Does Clomid raise estrogen?
One 66-man sequential chart review recorded a median estradiol rise of 17.50 pg/mL on clomiphene and a fall of 5.92 pg/mL on enclomiphene.
A larger 2026 retrospective conference abstract found no treatment difference in estradiol over time. The evidence does not support treating either pattern as a guaranteed drug effect.
References
- 1.Earl JA, Kim ED. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Review of Endocrinology and Metabolism. 2019;14(3):157-165.
- 2.Mikkelson TJ, et al. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertility and Sterility. 1986;46(3):392-396.
- 3.Helo S, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU International. 2017;119(1):171-176.
- 4.Saffati G, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;13(9):1984-1990.
- 5.Tienforti D, et al. Selective modulation of estrogen receptor in obese men with androgen deficiency: a systematic review and meta-analysis. Andrology. 2023;11(6):1067-1076.
- 6.Hohl A, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025;69(5):e250093.
- 7.Krzastek SC, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. Journal of Urology. 2019;202(5):1029-1035.
- 8.Thomas J, et al. Efficacy of clomiphene citrate versus enclomiphene citrate for male infertility treatment: a retrospective study. Cureus. 2023;15(7):e41476.
- 9.US National Library of Medicine. Clomiphene citrate tablets, USP: description and warnings on visual symptoms. DailyMed. Label updated 2025.
- 10.US Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: enclomiphene citrate. Meeting of 8 June 2022.
- 11.American Urological Association. Enclomiphene versus clomiphene hormone outcomes through 12 months. Journal of Urology. 2026 annual meeting abstract. doi:10.1097/01.JU.0001191396.05243.57.05.
- 12.European Commission. Commission implementing decision refusing marketing authorisation for EnCyzix (enclomifene). 6 April 2018.
- 13.US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories list. Updated 14 May 2026.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. It does not create a clinician and patient relationship. Talk to a licensed clinician about your own situation, and call your doctor or 911 for anything urgent.